Evidence map›Paper›PMID 30266952›Full record

ArticleScientific reports2018

Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival.

Karoline Fechter, Julia Feichtinger, Katharina Prochazka, Julia Judith Unterluggauer, Katrin Pansy, Elisabeth Steinbauer, Martin Pichler, Johannes Haybaeck, Andreas Prokesch, Hildegard T Greinix and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. TheInternational journal of molecular sciences · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Karoline FechterDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.ORCID http://orcid.org/0000-0002-6894-2438
Julia FeichtingerInstitute of Computational Biotechnology, Graz University of Technology, Graz, Austria.
Katharina ProchazkaDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Julia Judith UnterluggauerInstitute of Pathology, Medical University Graz, Graz, Austria.
Katrin PansyDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Elisabeth SteinbauerInstitute of Pathology, Medical University Graz, Graz, Austria.
Martin PichlerDivision of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Johannes HaybaeckInstitute of Pathology, Medical University Graz, Graz, Austria.ORCID http://orcid.org/0000-0001-5518-3359
Andreas ProkeschInstitute of Cell Biology, Histology and Embryology, Medical University Graz, Graz, Austria.
Hildegard T GreinixDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Christine Beham-SchmidInstitute of Pathology, Medical University Graz, Graz, Austria.
Peter NeumeisterDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
Gerhard G ThallingerInstitute of Computational Biotechnology, Graz University of Technology, Graz, Austria. gerhard.thallinger@tugraz.at.ORCID http://orcid.org/0000-0002-2864-5404
Alexander J A DeutschDivision of Hematology, Department of Internal Medicine, Medical University Graz, Graz, Austria. alexander.deutsch@medunigraz.at.ORCID http://orcid.org/0000-0003-0914-2809
Medical University of Graz · ATGraz University of Technology · ATInnsbruck Medical University · AT

Funding

Austrian Science Fund FWF T 923
6 · The paper itself

Abstract

The nuclear orphan receptor NR4A1 functions as tumour suppressor in aggressive lymphomas by pro-apoptotic genomic and non-genomic effects. Here, we immunohistochemically studied the clinico-pathological relevance of NR4A1 protein expression patterns in a cohort of 60 diffuse large B cell lymphoma (DLBCL) patients and non-neoplastic lymph nodes. We observed a significant association between high cytoplasmic NR4A1 and favourable cancer-specific survival and the germinal centre B cell-like subtype, respectively. Moreover, the percentage of lymphoma cells exhibiting cytoplasmic NR4A1 significantly correlated to those showing cleaved caspase 3. Complementary, functional profiling using gene set enrichment of Reactome pathways based on publicly available microarray data was applied to determine pathways potentially implicated in cytoplasmic localization of NR4A1 and validated by means of semi quantitative real-time PCR. The pathway analysis revealed changes in the ERK1/2 pathway, and this was corroborated by the finding that high cytoplasmic NR4A1 was associated with higher expression of ERK1/2 targets in our cohort. These data indicate that high cytoplasmic NR4A1 is associated with a favourable lymphoma-specific survival and highlights the importance of NR4A1 expression patterns as potential prognostic marker for risk assessment in aggressive lymphomas.

Indexed as

AgedCohort StudiesCytoplasmFemaleGene Expression Regulation, NeoplasticHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNuclear Receptor Subfamily 4, Group A, Member 1Survival AnalysisNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1

Identifiers

PMID30266952
PMCPMC6162226
OpenAlexW2892920179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.